ARISTADA LOGO (COLOUR)

View On IC.GC.CA

REGISTERED

on 28 Oct 2019

Last Applicant/ Owned by

ALKERMES PHARMA IRELAND LIMITED

1 Burlington Road, Connaught HouseDublin

Serial Number

1829304 filed on 24^th Mar 2017

Registration Number

TMA1060984 registered on 28^th Oct 2019

Registration expiry Date

28^th Oct 2029

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

M5X1G5

ARISTADA LOGO (COLOUR)

Trademark usage description

pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system Read More

Vienna Information

26 . 4 . 3

Rhombs or squares standing on one of the corners thereofLosanges ou carrés sur pointe

26 . 4 . 5

One quadrilateralUn quadrilatère

1 . 15 . 23

Vortices, rotary movements, tornadoes -- Note: Not including astronomic orbits (1.13.1), atomic orbits (1.13.1), concentric circles (26.1.4 or 26.1.5) and spirals (26.1.5).Tourbillons, mouvements rotatifs, tornade -- Note: Non compris les orbites astronomiques (1.13.1), les orbites atomiques (1.13.1), les cercles concentriques (26.1.4 ou 26.1.5) et les spirales (26.1.5).

26 . 4 . 2

RectanglesRectangles

26 . 4 . 9

Several quadrilaterals juxtaposed, joined or intersectingPlusieurs quadrilatères, juxtaposés, accolés ou se coupant

26 . 4 . 6

Quadrilateral figures with one or more convex or concave sides -- Note: Not including elongated surfaces with one or more convex or concave sides (25.3.1).Figures quadrilatérales à un ou plusieurs côtés convexes ou concaves -- Note: Non compris les surfaces allongées avec un ou plusieurs côtés convexes ou concaves (25.3.1).

26 . 4 . 24

Quadrilaterals with dark surfaces or parts of surfacesQuadrilatères avec surface ou partie de la surface foncée

29 . 1 . 1

Red, pink, orangeRouge, rose, orangé

29 . 1 . 4

BlueBleu

29 . 1 . 3

GreenVert

29 . 1 . 6

White, grey, silverBlanc, gris, argent

Classification Information

Class [005]
Pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, namely psychiatric disorders, namely schizophrenia, clinical depression, major depressive disorder, bipolar disorder, anxiety and panic disorders, substance abuse and dependence, depressive disorders namely mild to moderate to severe depressive episodes, anxiety disorders, psychosis, irritability associated with autistic disorder, schizoaffective disorder, treatment of Tourette's disorder, agitation associated with schizophrenia and bipolar mania, acute treatment of manic and mixed episodes associated with Bipolar I disorder, and reward disorders, namely eating disorders; pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of neurodegenerative diseases, namely Alzheimer's disease, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis (ALS); pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of cardiovascular diseases; pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of metabolic diseases, namely, diabetes, dyslipidemia and obesity; pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, namely psychiatric disorders, namely schizophrenia, clinical depression, major depressive disorder, bipolar disorder, anxiety and panic disorders, substance abuse and dependence, depressive disorders namely mild to moderate to severe depressive episodes, anxiety disorders, psychosis, irritability associated with autistic disorder, schizoaffective disorder, treatment of Tourette's disorder, agitation associated with schizophrenia and bipolar mania, acute treatment of manic and mixed episodes associated with Bipolar I disorder, and reward disorders, namely eating disorders

Classification kind code

Mark Details

Serial Number

1829304

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 42 on 31^st Jul 2019	Advertised
Submitted for opposition 26 on 9^th Jul 2019	Approved
Submitted for opposition 27 on 9^th Jul 2019	Approval Notice Sent
Submitted for opposition 15 on 7^th Jun 2019	Correspondence Created
Submitted for opposition 12 on 7^th Nov 2018	Extension of Time
Submitted for opposition 22 on 3^rd May 2018	Search Recorded
Submitted for opposition 20 on 3^rd May 2018	Examiner's First Report
Submitted for opposition 31 on 29^th Mar 2017	Formalized
Submitted for opposition 1 on 27^th Mar 2017	Created
Submitted for opposition 30 on 24^th Mar 2017	Filed